^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | D3L-001 (HER2 inhibitor, CD47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors
Excerpt:
...- Subject must have documented HER2 positivity (determined by immunohistochemistry [IHC], in situ hybridization [ISH], Next Generation Sequencing [NGS] or other analysis techniques as appropriate)....
Trial ID:
Source:
Title:
1873 / 12 - D3L-001, a novel bispecific antibody targeting HER2 and CD47, demonstrates potent preclinical efficacy in solid tumors.
Published date:
03/15/2023
Excerpt:
D3L-001 showed preferential binding to HER2/CD47 double positive tumor cells as compared to CD47 single positive cells. D3L-001 showed better anti-tumor effect than trastuzumab in a panel of solid tumor models, including but not limited to BC and GC cell lines or patient derived xenografts....D3L-001 also...showed synergistic in vivo efficacy, when combining with Pertuzumab or Paclitaxel, in breast HCC1954, JIMT-1 and gastric cancer N87 models....D3L-001 will be further evaluated in clinic for its potential as a novel treatment option in HER2-positive BC, GC and other solid tumors.
Secondary therapy:
paclitaxel
